Cardiac Failure Review最新文献_第8页

Out with the Old and In with the New: Primary Care Management of Heart Failure with Preserved Ejection Fraction 推陈出新：保留射血分数的心力衰竭的初级保健管理

Cardiac Failure Review Pub Date : 2022-01-01 DOI: 10.15420/cfr.2021.27

S. Stewart, Amy R Stewart, Laura H. Waite, J. Beilby

引用次数: 3

Multimodality Imaging in Valvular Structural Interventions. 多模态成像在瓣膜结构干预中的应用。

Cardiac Failure Review Pub Date : 2022-01-01 DOI: 10.15420/cfr.2022.10

Karine Grigoryan, Camelia Demetrescu, Ioannis Kasouridis, Olukayode Abiola, Pier Giorgio Masci, Didem Oguz, Giulia Benedetti, Mak SzeMun, Purvi Parwani, Rebecca Preston, Amedeo Chiribiri, Jane Hancock, Tiffany Patterson, Simon Redwood, Bernard Prendergast, Julia Grapsa

引用次数: 1

Adjunctive Techniques for Repair of Ischaemic Mitral Regurgitation. 辅助技术修复缺血性二尖瓣返流。

Cardiac Failure Review Pub Date : 2021-12-06 eCollection Date: 2021-03-01 DOI: 10.15420/cfr.2021.06

Sigrid L Johannesen, Colin M Barker, Melissa M Levack

{"title":"Adjunctive Techniques for Repair of Ischaemic Mitral Regurgitation.","authors":"Sigrid L Johannesen, Colin M Barker, Melissa M Levack","doi":"10.15420/cfr.2021.06","DOIUrl":"https://doi.org/10.15420/cfr.2021.06","url":null,"abstract":"Ischaemic mitral regurgitation is a complex process with debate in the literature as to the optimal treatment pathway. Multiple therapies are available to alleviate mitral regurgitation including medical management, transcatheter edge-to-edge repair, mitral valve repair and mitral valve replacement. Medical management with goal-directed therapy should be utilised in patients with heart failure and mild-to-moderate regurgitation. Transcatheter approaches are typically used in patients with prohibitive operative risk, although their use is expanding, especially in those with functional mitral regurgitation who are not responding to goal-directed medical therapy. It is generally accepted that patients with mild-to-moderate disease can avoid valve intervention if successful revascularisation is performed. A higher consideration should be given to valve replacement over repair in patients with severe mitral regurgitation in the setting of myocardial ischaemia. Operative course must be personalised to each patient, and continues to develop with improving technologies and ongoing research into optimal treatment.","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"7 ","pages":"e20"},"PeriodicalIF":0.0,"publicationDate":"2021-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e0/3d/cfr-07-e20.PMC8674630.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39872160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Isolated Left Ventricular Apical Hypoplasia. 孤立性左心室顶端发育不全。

Cardiac Failure Review Pub Date : 2021-12-06 eCollection Date: 2021-03-01 DOI: 10.15420/cfr.2021.24

Abhishek Dattani, Rachana Prasad

引用次数: 2

The Gap to Fill: Rationale for Rapid Initiation and Optimal Titration of Comprehensive Disease-modifying Medical Therapy for Heart Failure with Reduced Ejection Fraction. 空白填补:快速启动和最佳滴定综合疾病改善药物治疗心力衰竭与降低射血分数的基本原理。

Cardiac Failure Review Pub Date : 2021-11-26 eCollection Date: 2021-03-01 DOI: 10.15420/cfr.2021.18

Nicholas K Brownell, Boback Ziaeian, Gregg C Fonarow

引用次数: 19

Cardiac Sarcoidosis: When and How to Treat Inflammation. 心脏结节病:何时及如何治疗炎症。

Cardiac Failure Review Pub Date : 2021-11-22 eCollection Date: 2021-03-01 DOI: 10.15420/cfr.2021.16

Gerard T Giblin, Laura Murphy, Garrick C Stewart, Akshay S Desai, Marcelo F Di Carli, Ron Blankstein, Michael M Givertz, Usha B Tedrow, William H Sauer, Gary M Hunninghake, Paul F Dellaripa, Sanjay Divakaran, Neal K Lakdawala

{"title":"Cardiac Sarcoidosis: When and How to Treat Inflammation.","authors":"Gerard T Giblin, Laura Murphy, Garrick C Stewart, Akshay S Desai, Marcelo F Di Carli, Ron Blankstein, Michael M Givertz, Usha B Tedrow, William H Sauer, Gary M Hunninghake, Paul F Dellaripa, Sanjay Divakaran, Neal K Lakdawala","doi":"10.15420/cfr.2021.16","DOIUrl":"https://doi.org/10.15420/cfr.2021.16","url":null,"abstract":"Sarcoidosis is a complex, multisystem inflammatory disease with a heterogeneous clinical spectrum. Approximately 25% of patients with systemic sarcoidosis will have cardiac involvement that portends a poorer outcome. The diagnosis, particularly of isolated cardiac sarcoidosis, can be challenging. A paucity of randomised data exist on who, when and how to treat myocardial inflammation in cardiac sarcoidosis. Despite this, corticosteroids continue to be the mainstay of therapy for the inflammatory phase, with an evolving role for steroid-sparing and biological agents. This review explores the immunopathogenesis of inflammation in sarcoidosis, current evidence-based treatment indications and commonly used immunosuppression agents. It explores a multidisciplinary treatment and monitoring approach to myocardial inflammation and outlines current gaps in our understanding of this condition, emerging research and future directions in this field.","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"7 ","pages":"e17"},"PeriodicalIF":0.0,"publicationDate":"2021-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ba/e7/cfr-07-e17.PMC8674699.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39636573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 17

Left Ventricular Systolic Dysfunction Due to Atrial Fibrillation: Clinical and Echocardiographic Predictors. 心房颤动引起的左心室收缩功能障碍:临床和超声心动图预测因素。

Cardiac Failure Review Pub Date : 2021-11-22 eCollection Date: 2021-03-01 DOI: 10.15420/cfr.2021.17

Erez Marcusohn, Ofer Kobo, Maria Postnikov, Danny Epstein, Yoram Agmon, Lior Gepstein, Yaron Hellman, Robert Zukermann

{"title":"Left Ventricular Systolic Dysfunction Due to Atrial Fibrillation: Clinical and Echocardiographic Predictors.","authors":"Erez Marcusohn, Ofer Kobo, Maria Postnikov, Danny Epstein, Yoram Agmon, Lior Gepstein, Yaron Hellman, Robert Zukermann","doi":"10.15420/cfr.2021.17","DOIUrl":"https://doi.org/10.15420/cfr.2021.17","url":null,"abstract":"Background: Diagnosis of AF-induced cardiomyopathy can be challenging and relies on ruling out other causes of cardiomyopathy and, after restoration of sinus rhythm, recovery of left ventricular (LV) function. The aim of this study was to identify clinical and echocardiographic predictors for developing cardiomyopathy with systolic dysfunction in patients with atrial tachyarrhythmia. Methods: This retrospective study was conducted in a large tertiary care centre and compared patients who experienced deterioration of LV ejection fraction (EF) during paroxysmal AF, demonstrated by precardioversion transoesophageal echocardiography with patients with preserved LV function during AF. All patients had documented preserved LVEF at baseline (EF >50%) while in sinus rhythm. Results: Of 482 patients included in the final analysis, 80 (17%) had reduced and 402 (83%) had preserved LV function during the precardioversion transoesophageal echocardiography. Patients with reduced LVEF were more likely to be men and to have a more rapid ventricular response during AF or atrial flutter (AFL). A history of prosthetic valves was also identified as a risk factor for reduced LVEF. Patients with reduced LVEF also had higher incidence of tricuspid regurgitation and right ventricular dysfunction. Conclusion: In 'real-world' experience, male patients with rapid ventricular response during paroxysmal AF or AFL are more prone to LVEF reduction. Patients with prosthetic valves are also at risk for LVEF reduction during AF/AFL. Finally, tricuspid regurgitation and right ventricular dysfunction may indicate relatively long-standing AF with an associated reduction in LVEF.","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"7 ","pages":"e16"},"PeriodicalIF":0.0,"publicationDate":"2021-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/89/3a/cfr-07-e16.PMC8674700.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39636571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Effect of Statin Intensity on the Progression of Cardiac Allograft Vasculopathy. 他汀类药物强度对同种异体心脏移植血管病变进展的影响。

IF 4.2

Cardiac Failure Review Pub Date : 2021-11-12 eCollection Date: 2021-03-01 DOI: 10.15420/cfr.2021.07

Tracey M Ellimuttil, Kimberly Harrison, Allman T Rollins, Irene D Feurer, Scott A Rega, Jennifer Gray, Jonathan N Menachem

{"title":"Effect of Statin Intensity on the Progression of Cardiac Allograft Vasculopathy.","authors":"Tracey M Ellimuttil, Kimberly Harrison, Allman T Rollins, Irene D Feurer, Scott A Rega, Jennifer Gray, Jonathan N Menachem","doi":"10.15420/cfr.2021.07","DOIUrl":"10.15420/cfr.2021.07","url":null,"abstract":"Background: In the non-transplant population, hyperlipidaemia has shifted from targeting LDL goals to statin intensity-based treatment. It is unknown whether this strategy is also beneficial in cardiac transplantation. Methods: This single-centre retrospective study evaluated the effect of statin use and intensity on time to cardiac allograft vasculopathy (CAV) after cardiac transplantation. Kaplan-Meier and Cox proportional hazards regression survival methods were used to assess the association of statin intensity and median post-transplant LDL on CAV-free survival. Results: The study involved 143 adults (71% men, average follow-up of 25 ± 14 months) who underwent transplant between 2013 and 2017. Mean CAV-free survival was 47.5 months (95% CI [43.1-51.8]), with 29 patients having CAV grade 1 or greater. Median LDL was not associated with time to CAV (p=0.790). CAV-free survival did not differ between intensity groups (p=0.435). Conclusion: Given the non-statistically significant difference in time to CAV with higher intensity statins, the data suggest that advancing moderate- or high-intensity statin after cardiac transplantation may not provide additional long-term clinical benefit. Trial registration: Not applicable.","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"7 ","pages":"e15"},"PeriodicalIF":4.2,"publicationDate":"2021-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/7d/e6/cfr-07-e15.PMC8609416.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39636569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

How to Implant His Bundle and Left Bundle Pacing Leads: Tips and Pearls. 如何植入他的束和左束起搏导线:提示和珍珠。

Cardiac Failure Review Pub Date : 2021-08-06 eCollection Date: 2021-03-01 DOI: 10.15420/cfr.2021.04

Shunmuga Sundaram Ponnusamy, Pugazhendhi Vijayaraman

引用次数: 17

Unknown Risks of Transplantation in Adults with Congenital Heart Disease. 成人先天性心脏病移植的未知风险。

Cardiac Failure Review Pub Date : 2021-08-06 eCollection Date: 2021-03-01 DOI: 10.15420/cfr.2021.09

Aniket S Rali, Angela Weingarten, Emily Sandhaus, Richa Gupta, Allman Rollins, David Bichell, Nhue Do, D Marshall Brinkley, Kelly H Schlendorf, Daniel Freno, Keki Balsara, Jonathan N Menachem

引用次数: 1